Category: Ocrevus

New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis

Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a…

Stuart Schlossman

Shorter Ocrelizumab Infusion Accepted for FDA Review

The FDA has accepted an sBLA for a version of Genentech’s ocrelizumab with a shorter administration time for the treatment…

Stuart Schlossman

Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS

Feb 17, 2020 – By Ed Tobia Ocrevus (ocrelizumab) bolted out of the starting gate after it was approved for use…

Stuart Schlossman

See the latest open-label extension data for Ocrevus

Examine 2 years of controlled and 3+ years of open-label extension efficacy and safety data. View in  Browser Important Safety Information…

Stuart Schlossman

Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in…

Stuart Schlossman

Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

Published: Sep 04, 2019 Sept. 4, 2019 05:00 UTC Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal…

Stuart Schlossman

GENENTECH TO PRESENT NEW OCREVUS (OCRELIZUMAB) DATA ANALYSES SHOWING SIGNIFICANT REDUCTION OF DISABILITY PROGRESSION IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS AT THE AAN ANNUAL MEETING

New analyses show the effect of OCREVUS on reducing the risk of disability progression is associated with exposure and lower…

Stuart Schlossman

New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio

Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor…

Stuart Schlossman

Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports

December 18, 2018 Pretreating multiple sclerosis patients with antihistamines more extensively and with hydration can significantly reduce — by 60% — the likelihood…

Stuart Schlossman

Ocrevus Now Available Through NHS Scotland to Treat RRMS

Dec 12, 2018 Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with…

Stuart Schlossman

Categories

Latest Blog Posts